Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in:

28.06.2022 | Clinical trial

Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel

verfasst von: Ciao-Sin Chen, Ellen M. Lavoie Smith, Kathleen A. Stringer, N. Lynn Henry, Daniel L. Hertz

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is the major treatment-limiting toxicity of paclitaxel, which predominantly presents as sensory symptoms, with motor symptoms in some patients. Differentiating CIPN into subtypes has been recommended to direct CIPN research. The objective of this study was to investigate whether sensory and motor CIPN are distinct subtypes with different predictive biomarkers in patients with breast cancer receiving paclitaxel.

Methods

Data were from a prospective cohort of 60 patients with breast cancer receiving up to 12 weekly infusions of 80 mg/m2 paclitaxel (NCT02338115). European Organisation for Research and Treatment of Cancer Quality of Life questionnaire CIPN20 was used to evaluate CIPN. Clusters of the time course of sensory (CIPNS), motor (CIPNM), and the difference between sensory and motor (CIPNS–CIPNM) were identified using k-means clustering on principal component scores. Predictive metabolomic biomarkers of maximum CIPNS and CIPNM were investigated using linear regressions adjusted for baseline CIPN, paclitaxel pharmacokinetics, and body mass index.

Results

More sensory than motor CIPN was found (CIPNS change: mean = 10.8, ranged [−3.3, 52.1]; CIPNM change: mean = 3.5, range: [−7.5, 35.0]). Three groups were identified with No CIPN, Mixed CIPN, and Sensory-dominant CIPN (maximum CIPNS: mean = 12.7 vs. 40.9 vs. 74.3, p < 0.001; maximum CIPNM: mean = 5.4 vs. 25.5 vs. 36.1, p < 0.001; average CIPNS–CIPNM: mean = 2.8 vs. 5.8 vs. 24.9, p < 0.001). Biomarkers of motor CIPN were similar to previously identified biomarkers of sensory CIPN, including lower serum histidine (p = 0.029).

Conclusion

Our findings suggest that sensory and motor CIPN co-occur and may not have differentiating metabolic biomarkers. These findings need to be validated in larger cohorts of patients treated with paclitaxel and other neurotoxic agents to determine the optimal approach to predict, prevent, and treat CIPN and improve patients’ outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd et al (2018) Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Natl Cancer Inst 110(6):669–676PubMedPubMedCentralCrossRef
2.
Mustafa Ali M, Moeller M, Rybicki L, Moore HCF (2017) Long-term peripheral neuropathy symptoms in breast cancer survivors. Breast Cancer Res Treat 166(2):519–526PubMedCrossRef
3.
Simon NB, Danso MA, Alberico TA, Basch E, Bennett AV (2017) The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res 26(10):2763–2772PubMedCrossRef
4.
Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333PubMedPubMedCentralCrossRef
5.
Osmani K, Vignes S, Aissi M, Wade F, Milani P, Lévy BI, Kubis N (2012) Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol 259(9):1936–1943PubMedCrossRef
6.
Kuroi K, Shimozuma K (2004) Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast cancer (Tokyo, Japan) 11(1):92–99CrossRef
7.
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325–3348PubMedCrossRef
8.
Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40(7):872–882PubMedCrossRef
9.
Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17PubMedCrossRef
10.
Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47(1):115–118PubMedCrossRef
11.
Boyette-Davis JA, Cata JP, Driver LC, Novy DM, Bruel BM, Mooring DL, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM (2013) Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol 71(3):619–626PubMedCrossRef
12.
Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S (2017) Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 35(23):2604–2612PubMedPubMedCentralCrossRef
13.
Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K (2016) The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 73(7):860–866PubMedPubMedCentralCrossRef
14.
Dorsey SG, Kleckner IR, Barton D, Mustian K, O’Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman DL, Hohmann AG et al (2019) The National Cancer Institute Clinical Trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst 111(6):531–537PubMedPubMedCentralCrossRef
15.
Themistocleous AC, Crombez G, Baskozos G, Bennett DL (2018) Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain 159(Suppl 1):S31–S42PubMedPubMedCentralCrossRef
16.
Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O’Mara A, Smith AG, Dastros-Pitei D et al (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91(9):403–413PubMedPubMedCentralCrossRef
17.
Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S et al (2019) Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Supportive Care Cancer 27(10):3729–3737CrossRef
18.
Wang M, Cheng HL, Lopez V, Sundar R, Yorke J, Molassiotis A (2019) Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer 19(1):1151PubMedPubMedCentralCrossRef
19.
Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF et al (2018) Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res 24(15):3602–3610PubMedPubMedCentralCrossRef
20.
Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS et al (2020) Genomewide meta-analysis validates a role for S1PR1 in microtubule targeting agent-induced sensory peripheral neuropathy. Clin Pharmacol Ther 108(3):625–634PubMedCrossRef
21.
Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz DL et al (2015) Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy. Clinical Cancer Res 21(19):4337–4346CrossRef
22.
Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier A-L, Hiller L, Burns R, Jones L et al (2014) Replication of genetic polymorphisms reported to be associated with Taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 20(9):2466–2475PubMedCrossRef
23.
Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I et al (2013) Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clinical Cancer Res 19(2):491–499CrossRef
24.
Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, Mielgo X, Gonzalez-Neira A, Robledo M, Avall-Lundqvist E et al (2013) Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 50(9):599–605PubMedCrossRef
25.
Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL et al (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clinical Cancer Res 18(18):5099–5109CrossRef
26.
Chen EI, Crew KD, Trivedi M, Awad D, Maurer M, Kalinsky K, Koller A, Patel P, Kim Kim J, Hershman DL (2015) Identifying predictors of Taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS ONE 10(12):e0145816PubMedPubMedCentralCrossRef
27.
Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, Henry NL, Stringer KA, Hertz DL (2018) Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 171(3):657–666PubMedPubMedCentralCrossRef
28.
Jennaro TS, Fang F, Kidwell KM, Smith EML, Vangipuram K, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Henry NL et al (2020) Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 180(3):707–714PubMedPubMedCentralCrossRef
29.
Kramer R, Bielawski J, Kistner-Griffin E, Othman A, Alecu I, Ernst D, Kornhauser D, Hornemann T, Spassieva S (2015) Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. Faseb j 29(11):4461–4472PubMedPubMedCentralCrossRef
30.
Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462PubMedCrossRef
31.
Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42(1):24–30PubMedCrossRef
32.
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10):1633–1642PubMedCrossRef
33.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470PubMedCrossRef
34.
De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S (2015) Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol 96(1):34–45PubMedCrossRef
35.
Carlson K, Ocean AJ (2011) Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 11(2):73–81PubMedCrossRef
36.
Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6(6):455–467PubMed
37.
Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66(3):218–228PubMedCrossRef
38.
Hikino H, Kawashima M, Yamada T, Ozaki N (2006) Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient. Int J Clin Oncol 11(4):332–335PubMedCrossRef
39.
Augusto C, Pietro M, Cinzia M, Sergio C, Sara C, Luca G, Scaioli V (2008) Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neurooncol 86(1):89–99PubMedCrossRef
40.
Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP et al (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19(1):132PubMedPubMedCentralCrossRef
41.
Smith EML, Banerjee T, Yang JJ, Bridges CM, Alberti P, Sloan JA, Loprinzi C (2019) Psychometric testing of the European Organisation for research and treatment of cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy 20-item scale using pooled chemotherapy-induced peripheral neuropathy outcome measures standardization and alliance for clinical trials in oncology A151408 study data. Cancer Nurs 42(3):179–189PubMedCrossRef
42.
Smith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, Le-Rademacher J, Yang JJ (2019) Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. Supportive Care Cancer 27(7):2599–2608CrossRef
43.
Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK (2017) Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Qual Life Res 26(11):2999–3010PubMedCrossRef
44.
Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 questionnaire. Qual Life Res 22(10):2787–2799PubMedPubMedCentralCrossRef
45.
Ekholm E, Rantanen V, Antila K, Salminen E (1997) Paclitaxel changes sympathetic control of blood pressure. Eur J Cancer 33(9):1419–1424PubMedCrossRef
46.
Hertz DL (2019) Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy. Pharmacogenomics J 19(5):411–416PubMedPubMedCentralCrossRef
47.
Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, Choi SK, Lee JT, Wood WA, Anders CK et al (2019) Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer 125(17):2945–2954PubMedCrossRef
48.
Di Maio M, Basch E, Bryce J, Perrone F (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319–325PubMedCrossRef
49.
Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Supportive Care Cancer 17(8):1071–1080CrossRef
50.
Chen C-S, Kim J, Garg N, Guntupalli H, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan BC, Hertz DL (2021) Chemotherapy-induced peripheral neuropathy detection via a smartphone app: cross-sectional pilot study. JMIR Mhealth Uhealth 9(7):e27502PubMedCentralCrossRef
51.
Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS et al (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33(1):58–64PubMedCrossRef
Metadaten
Titel
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel
verfasst von
Ciao-Sin Chen
Ellen M. Lavoie Smith
Kathleen A. Stringer
N. Lynn Henry
Daniel L. Hertz
Publikationsdatum
28.06.2022
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06652-x

Weitere Artikel der Ausgabe 3/2022

Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention

  • Clinical trial

miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

  • Review

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer

  • Open Access
  • Clinical trial

Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis

  • Epidemiology

Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence

  • Epidemiology

Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density

  • Epidemiology

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise